Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 934 • 2012 ACR/ARHP Annual Meeting
Direct Medical Cost Associated with Organ System Involvement in a Commercially Insured Population with Systemic Lupus Erythematosus in the United States
Alan Oglesby¹, Emily Durden², Siva Narayanan³, Paul Juneau⁴ and Kathleen L. Wilson⁵, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Thomson Reuters, Austin, TX, ³Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ⁴Truven Health Analytics, Washington, DC, ⁵Thomson Reuters Healthcare, Cambridge, MA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, as well as the joints and…
Abstract Number: 619 • 2012 ACR/ARHP Annual Meeting
Elevated Plasma Levels of CXCL2 and CXCL10 Have Distinct Predictive Value in Systemic Lupus Erythematosus
Felipe Andrade¹, Ehtisham Akhter², Hong Fang³ and Michelle Petri³, ¹Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Serum levels of chemokines have been previously used as downstream markers of the interferon (IFN) pathway in SLE. CXCL2 (GROB) and CXCL10 (IP-10) have…
Abstract Number: 2247 • 2012 ACR/ARHP Annual Meeting
The First Report of Desensitization to Trimethoprim/Sulfamethoxazole in Patients with Systemic Lupus Eryhtematosus
Yasuhiro Suyama¹, Mitsumasa Kishimoto², Hiroto Nakano³, Ken-ichi Yamaguchi¹, Hisanori Shimizu⁴, Ryo Rokutanda⁴, Chisun Min², Yuri Ohara⁴, Yoichiro Haji², Kazuo Matsui⁵, Akira Takeda⁶, Yukio Matsui⁷ and Masato Okada⁷, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ³Department of Rheumatology, Kameda Medical Center, Kamogawa City, Japan, ⁴Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁶Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, ⁷Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Trimethoprin-sulfamethoxazole (TMP/SMX) is the most effective and widely used prophylactic medication in immunocompromised patients. Some diseases are well-known to cause allergic reactions including human…
Abstract Number: 935 • 2012 ACR/ARHP Annual Meeting
Primary Care Preventive Services in Patients with Systemic Lupus Erythematosus Compared to Others in Their Community
Cristina Drenkard¹, Kimberley Rask², Gaobin Bao³, Gnanesh Patel⁴, Suparna Bagchi⁵ and S. Sam Lim⁶, ¹Medicine, Div Rheumatology, Emory University, Atlanta, GA, ²Health Policy and Management, Emory University, Atlanta, GA, ³Medicine, Emory University, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Georgia Department of Public Health, Atlanta, GA, ⁶Emory University School of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic illness frequently complicated by infections, cardiovascular disease (CVD) and cancer. Primary care preventive services (PCS) are recommended…
Abstract Number: 624 • 2012 ACR/ARHP Annual Meeting
Excess Health Care Utilization Prior to Diagnosis of Systemic Lupus Erythematosus in England
Amy Steffey¹, Trung N. Tran¹, Jie Li¹ and Herve Caspard², ¹Epidemiology, Clinical Development, MedImmune, Gaithersburg, MD, ²Epidemiology, Clinical Development, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic auto-immune disease resulting in significant excess morbidity and health care utilization. Since time of disease onset is…
Abstract Number: 2252 • 2012 ACR/ARHP Annual Meeting
Epratuzumab-Treated Systemic Lupus Erythematosus Patients Report Improvements in Health-Related Quality of Life: Final Results from an Open-Label Extension Study (SL0006)
V. Strand¹, K. Hobbs², D.J. Wallace³, K. Kalunian⁴, B. Kilgallen⁵, E. Nikaï⁶, W.A. Wegener⁷ and D.M. Goldenberg⁸, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Denver Arthritis Clinic, Denver, CO, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴UCSD School of Medicine, La Jolla, CA, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Brussels, Belgium, ⁷Immunomedics Inc, Morris Plains, NJ, ⁸Centre for Molecular Medicine and Immunology, Morris Plains, NJ
Background/Purpose: Epratuzumab, a monoclonal antibody targeting CD22, is in development for the treatment of systemic lupus erythematosus (SLE). Two randomized controlled trials (RCTs): ALLEVIATE 1…
Abstract Number: 937 • 2012 ACR/ARHP Annual Meeting
Changes in Ten Year Survival Among SLE Patients At an Academic Center in North America (1970-2011)
Joseph F. Merola¹, Bonnie L. Bermas², Bing Lu¹, Peter Hsun Tsao¹, Tabatha Norton¹, Christina Iversen¹, Elizabeth W. Karlson², Peter H. Schur¹ and Karen H. Costenbader¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Data from other large SLE cohorts have suggested improving survival among SLE patients in recent years with protective effects from antimalarial use and less…
Abstract Number: 625 • 2012 ACR/ARHP Annual Meeting
Control of Hypertension and Hypercholesterolemia Is Not Associated with a Decreased Rate of Atherosclerotic Vascular Events in Patients with Systemic Lupus Erythematosus
Joanna Ueng¹, D. D. Gladman², Dominique Ibanez³ and Murray B. Urowitz³, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology. It has been shown that patients with SLE are at a higher…
Abstract Number: 2254 • 2012 ACR/ARHP Annual Meeting
Discoid Lupus in Patients with Systemic Lupus Erythematosus
Ghassan AlJohani¹, Dominique Ibanez², D. D. Gladman¹ and Murray B. Urowitz², ¹Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Discoid lupus lesions occur in 20% of patients with SLE at some point in their disease course, and are often resistant to therapy.…
Abstract Number: 938 • 2012 ACR/ARHP Annual Meeting
Hospitalizations in Systemic Lupus Erythematosus: A Longitudinal Study
Hong Fang¹, Jie Xu² and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hospitalizations are one of the major direct costs in SLE. A review of studies looking at the contributions of different medical components to the…
Abstract Number: 605 • 2012 ACR/ARHP Annual Meeting
Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Eliza F. Chakarvarty¹, Kaleb Michaud², Robert S. Katz³ and Frederick Wolfe⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ²Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, ³Rush University Medical Center, Chicago, IL, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Herpes zoster (HZ) is the painful reactivation of latent varicella zoster virus infection. The incidence of HZ may be increased in some autoimmune…
Abstract Number: 2257 • 2012 ACR/ARHP Annual Meeting
Association of Low Vitamin D with High Disease Activity in an Australian Systemic Lupus Erythematosus Cohort
Kristy S. Yap¹, Alberta Y. Hoi² and Eric F. Morand², ¹Rheumatology, Monash Medical Centre, Clayton, Australia, ²Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
Background/Purpose: Previous cross-sectional studies suggest that low vitamin D may be associated with higher disease activity in SLE. Vitamin D status varies with geographic location…
Abstract Number: 940 • 2012 ACR/ARHP Annual Meeting
Incidence of Systemic Lupus Erythematosus in England, 1998-2010
Herve Caspard¹, Amy Steffey², Jie Li² and Trung N. Tran², ¹Epidemiology, Clinical Development, MedImmune LLC, Gaithersburg, MD, ²Epidemiology, Clinical Development, MedImmune, Gaithersburg, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic auto-immune disease associated with a wide spectrum of clinical manifestations and increased mortality. The most recent data…
Abstract Number: 2683 • 2012 ACR/ARHP Annual Meeting
Interferon-Associated Cytokine and Chemokine Expression in Patients with Serologically Active Clinically Quiescent (SACQ) Systemic Lupus Erythematosus (SLE)
Amanda J. Steiman¹, Murray B. Urowitz², Dominique Ibanez², Carolina Landolt-Marticorena³, Dafna D. Gladman⁴ and Joan E. Wither⁵, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ⁵1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Interferon-α (IFN-α) plays a prominent pro-inflammatory role in SLE. Studies suggest clinical/serologic discordance may illuminate SLE pathophysiology: peripheral IFN-α production is blunted in autoantibody-producing,…
Abstract Number: 2260 • 2012 ACR/ARHP Annual Meeting
Serum DNAse I Anti DNAse I Antibodies , CRP and Antibodies to CRP Relation to Disease Activity in Systemic Lupus Eryhtematous: Longitudinal Studies
Ramnath Misra¹, Avadesh Pratap², Amit Singh¹ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunlogy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Technician, Lucknow, India
Background/Purpose: Defective clearance of both nuclesomes and immune complexes has been suggested to intiate and perpetuate the disease. Defects in DNAse I gene in mice have shown SLE like symptoms,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].